Nov 13, 2025 04:09PM BioAtla, Inc. (BCAB) Reports In-Line Q3 EPS

Oct 23, 2025 08:02AM BioAtla presents data on ozuriftamab vedotin for throat cancer treatment

Sep 9, 2025 04:02AM Citizens JMP Reiterates Market Perform Rating on BioAtla Inc. (BCAB)

Aug 13, 2025 01:53AM Citizens JMP Downgrades BioAtla Inc. (BCAB) to Market Perform

Aug 7, 2025 04:10PM BioAtla, Inc. (BCAB) Misses Q2 EPS by 6c

Jul 3, 2025 08:00AM BioAtla (BCAB) Presents Data from Ongoing Dose Escalation of BA3182

Jun 2, 2025 08:07AM BioAtla (BCAB) Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

May 30, 2025 05:01AM Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025

May 7, 2025 04:09AM Citizens JMP Reiterates Market Outperform Rating on BioAtla Inc. (BCAB)

May 6, 2025 04:07PM BioAtla, Inc. (BCAB) Tops Q1 EPS by 13c

Apr 21, 2025 04:21AM Citizens JMP Reiterates Market Outperform Rating on BioAtla Inc. (BCAB)

Mar 31, 2025 05:28AM BioAtla Inc. (BCAB) PT Lowered to $1 at Citizens JMP

Mar 28, 2025 06:32AM BioAtla Inc. (BCAB) PT Lowered to $10 at BTIG

Dec 20, 2024 09:01AM BioAtla (BCAB) Announces 9.68M Share Offering at $1.19/sh

Nov 13, 2024 06:51AM H.C. Wainwright Downgrades BioAtla Inc. (BCAB) to Neutral

Nov 7, 2024 04:27PM BioAtla, Inc. (BCAB) Tops Q3 EPS by 19c

Sep 23, 2024 07:31AM BioAtla (BCAB) and Context Therapeutics (CNTX) Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362

Sep 16, 2024 08:01AM BioAtla (BCAB) Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability

Aug 20, 2024 06:03AM BTIG Reiterates Buy Rating on BioAtla Inc. (BCAB)

Aug 8, 2024 04:20PM BioAtla, Inc. (BCAB) Tops Q2 EPS by 1c